DRAC President Hit with FDA Warning Letter for Trial Protocol Violations

By Zachary Brennan

- Last updated on GMT

Related tags: Oxycodone, Food and drug administration

DRAC President Hit with FDA Warning Letter for Protocol Violations
The US FDA has sent a warning letter to CRO Drug Research and Analysis Corp. founder and president Henry Frazer for failing to adhere to the agency’s regulations governing clinical trials.

The warning letter​ released Tuesday follows a Form 483 from last year and is related to an FDA inspection from Sept. and Oct. of 2012 in which Frazer was found to have not adhered “to the applicable statutory requirements and FDA regulations governing the conduct of clinical investigations​.”

Specifically, the FDA said Frazer failed to follow protocols that said “that you dispense a handheld electronic device (LogPad) to subjects​” at a visit prior to surgery, and that “the subjects record their pain assessments in the LogPad during the study​.”  Frazer did not dispense a LogPad to one subject “because the subject was sedated and on a ventilator​,” while five pain assessments for another subject “were entered into the LogPad by the study coordinator, rather than by the subject​.”

Although you explained how the violation occurred, you failed to provide a corrective action plan to prevent recurrence of similar violations in the future​,” the FDA said. 

The agency added that based on Frazer’s response to the Form 483, “we have concerns that your study coordinator may have inappropriately entered data into the LogPad for other subjects, as well. 

“We request that you inform us, in writing, of the extent to which pain-assessment data were not obtained directly from the subjects; the extent to which anyone other than the subjects entered pain-assessment data into LogPads; and how you intend to prevent the recurrence of similar violations in the future​.”

The FDA also said one patient did not meet the study protocol’s inclusion criteria.

In addition, the protocol prohibited the use of pain medications Percocet and Oxycontin (oxycodone hydrochloride), although one patient received Percocet and another received Oxycontin.

Your failure to maintain adequate and accurate case histories by failing to maintain adequate and accurate pain assessments compromised the validity and integrity of data captured at your site​,” the agency said.

Frazer did not respond to a request for comment by press time.

Related news

Show more

Related products

show more

Strategic Approach to Immunogenicity Assessment

Strategic Approach to Immunogenicity Assessment

Altasciences | 17-May-2022 | Technical / White Paper

In this issue of The Altascientist we provide a detailed overview on the different goals and challenges that are presented by the validation of immunogenicity...

Governing and Maintaining Clinical Data Standards

Governing and Maintaining Clinical Data Standards

Veeva | 10-May-2022 | Technical / White Paper

Investing in data standards plays a huge role in improving the quality of clinical studies. But often, people don’t use the standards correctly, there...

What the Best Clinical Study Build Pros Do

What the Best Clinical Study Build Pros Do

Formedix | 09-May-2022 | Technical / White Paper

Getting your clinical study designed and built ready for data collection takes A LOT of work and expertise… you've got to do all your CRF designs;...

What should a clinical metadata repository do?

What should a clinical metadata repository do?

Formedix | 18-Apr-2022 | Technical / White Paper

Choosing a clinical metadata repository (MDR) software can be a tough task as the capabilities and features of your chosen MDR could make or break your...

Related suppliers

Follow us

Products

View more

Webinars